ArticleEuropean geriatric medicine2026
Circulating PBX1 and age-related sarcopenia phenotypes: metabolic mediation analyses in a community-based study.
Article in European geriatric medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biomarkers and Early Mechanisms of Sarcopenia: Central Roles of Mitochondrial Dysfunction, Inflammaging, Cellular Senescence, and Neuromuscular Degeneration.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposeTo determine whether circulating PBX1 is associated with AWGS2019-defined sarcopenia phenotypes in older adults, and whether alanine-related metabolites mediate the PBX1-ASMI association.
methodsWe enrolled 324 adults aged 60 years or older from Licha Town, Qingdao, China (2022-2023) and classified sarcopenia using AWGS 2019. Plasma PBX1 was quantified by ELISA, and targeted plasma metabolite profiling was performed by LC-MS/MS. Primary outcomes were appendicular skeletal muscle mass index (ASMI), 6-m gait speed, and maximal handgrip strength. Independent associations were estimated using multivariable linear regression. Mediation models quantified indirect statistical components of the PBX1-ASMI association through prespecified metabolites (alanine and the lactic acid/alanine ratio) with bootstrap confidence intervals. ROC analyses assessed discrimination for sarcopenia and severe sarcopenia.
resultsHigher plasma PBX1 was independently associated with greater ASMI, faster gait speed, and stronger handgrip strength (all P < 0.001). PBX1 was positively associated with alanine and inversely associated with the lactic acid/alanine ratio. Alanine and the lactic acid/alanine ratio accounted for 10.79% (P = 0.017) and 10.11% (P = 0.002) of the PBX1-ASMI association, respectively; indirect components for gait speed and handgrip strength were not statistically significant. PBX1 discriminated sarcopenia (AUC 0.748) and severe sarcopenia (AUC 0.771), with high negative predictive value for severe sarcopenia at Youden-optimal thresholds.
conclusionCirculating PBX1 is independently associated with preserved muscle mass and function in older adults. PBX1 warrants external validation and longitudinal evaluation as a clinically informative correlate and candidate adjunctive biomarker for sarcopenia risk stratification.
Indexed as
Identifiers
42081027What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.